- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
10/22/13 8:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that, having achieved technical milestones related to manufacturing, it will continue the development program for Remoxy® (oxycodone) Extended-Release Capsules CII. Following guidance received from the U.S. Food and Drug Administration (FDA) earlier this year, Pfizer will proceed with the additional clinical studies and other actions required to address the Complete Response Letter received in June 2011. more...
Pfizer Announces Top-Line Results Of The First Two Of Five Phase 3 Clinical Trials Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis10/9/13 8:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today top-line results from two Phase 3 clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A3921111). These are the first two of five studies in the Phase 3 Oral Psoriasis Treatment (OPT) Program, one of the largest global clinical trialmore...
Pfizer Inc. Announces FDA Approval of DUAVEE™ (conjugated estrogens/ bazedoxifene) for the Treatment of Moderate-to-Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause and the Prevention of Postmenopausal Osteoporosis 10/3/13 4:14 pm EDT
DUAVEE is the first and only therapy to pair conjugated estrogens with an estrogen agonist/antagonist, also known as a selective estrogen receptor modulator (SERM) NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE), a leader in the development of treatments for menopausal symptoms, is pleased to announce that the United States Food and Drug Administration (FDA) has approved DUAVEETM (conjugated estrogens/bazedoxifene) 0.45mg / 20mg tablets, a novel therapy for women with a uterus, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis . Whenmore...
International Atherosclerosis Society And Pfizer Independent Grants For Learning & Change Collaborate On New Grant Opportunity10/2/13 5:04 pm EDTNEW YORK--(BUSINESS WIRE)--Today the International Atherosclerosis Society (IAS) and Pfizer Independent Grants for Learning & Change (IGLC) announce their collaboration on a new grant opportunity focused on improving care for patients around the world with medium or high levels of cardiovascular risk, with a particular focus on dyslipidemia. The Request for Proposals (RFP) being issued today by both organizations is intended to encourage organizations tomore...
10/1/13 11:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 29, 2013. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2013 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizermore...
9/30/13 11:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced the election of Shantanu Narayen to its Board of Directors, effective September 27, 2013. Mr. Narayen also was appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board. Mr. Narayen, 50, is the President and Chief Executive Officer (CEO) of Adobe Systems Incorporated and serves on Adobe’s Board of Directors. Prior to his appointment as CEO in December 2007, he held variousmore...
Advil® Becomes Official Pain Reliever of the National Hockey League and the 30 Team Athletic Trainers9/30/13 10:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Consumer Healthcare, a unit of Pfizer, Inc. (NYSE:PFE) and the maker of Advil®, the #1 selling over-the-counter pain reliever in the United States, and the National Hockey League (NHL) today announced Advil® is an Official Partner and the Official Pain Reliever of the NHL® and the 30 NHL athletic trainers in North America for the 2013-14 season. Under the agreement, Advil® is also an Official Partner and the Official Pain Relievermore...
9/3/13 10:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Executive Vice President, Business Operations and Chief Financial Officer, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2013 at 4:05 p.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Morgan Stanley Global Healthcare Conference” link inmore...
Pfizer Completes Pneumococcal Pneumonia Case Accrual For CAPiTA, Adult Vaccine Clinical Trial of Prevenar 13*8/29/13 8:00 am EDT
Top-line Results Expected in Early 2014NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the completion of pneumonia case accrual in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) 65 years of age and older. CAPiTA, the largest trial of its kind, was designed to evaluate whether Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) is effective in preventing community-acquired pneumonia (CAP) caused by the 13 pneumococcal serotypes included inmore...
7/30/13 3:49 am EDT
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2013. As a result of the full disposition of Zoetis(1) on June24, 2013, the financial results of the Animal Health business are now reported as a discontinued operation in the condensed consolidated statements of income for second-quarter and year-to-date for both 2013 and 2012. Results and guidance are summarized below.OVERALL RESULTS($ in millions, exceptper share amounts) more...
- Results Reflect the Animal Health Business (Zoetis(1)) as a Discontinued Operation for Second-Quarter and Year-to-Date 2013 and 2012
- Second-Quarter 2013 Revenues of $13.0 Billion, Adjusted Diluted EPS(2) of $0.56 and Reported Diluted EPS(3) of $1.98
- Repurchased $3.3 Billion and $8.7 Billion of Common Stock in Second-Quarter and to Date in 2013, Respectively
- Accepted 405.1 Million Shares of Common Stock in Exchange for Remaining Zoetis(1) Interest
- Reaffirmed All Components of Adjusted Financial Guidance
- Announced Plan to Create Separate, Internal, Global Innovative and Value Businesses